RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Account Payables
Amounts the company owes suppliers for goods and services received.
RenovoRx, Inc.NASDAQ: RNXT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 15.7% from a year ago
Account payables stood at $1.12M at the end of Q1 FY2026, up 15.7% from a year earlier and up 40.1% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.
Context
- Account payables amounted to 8.0% of total assets at the end of Q1 FY2026, up 2.0 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 799K USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +11.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 799K | +36.3% |
| FY2024 | 2024-12-31 | 586K | +4.5% |
| FY2023 | 2023-12-31 | 561K | +5.1% |
| FY2022 | 2022-12-31 | 534K | +1.7% |
| FY2021 | 2021-12-31 | 525K | — |
Account Payables vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 account payables of $1.12M is the 5th highest of the 6 companies compared; the peer median is $2.98M.
- Its year-over-year change of +15.7% is the 3rd highest of 6, against a peer median of +13.4%.
- Account payables amounts to 8.0% of total assets for RNXT, versus a peer median of 8.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $26.42M | +13.4% | +65.7% | 24.6% | |
| Mar 2026 | $5.28M | +285.0% | -13.2% | 32.5% | |
| Mar 2026 | $2.98M | +62.0% | +20.5% | 8.4% | |
| Mar 2026 | $1.54M | -23.9% | +35.8% | 8.0% | |
| Mar 2026 | $1.12M | +15.7% | +14.4% | 8.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding RNXT) | $2.98M | +13.4% | +28.1% | 8.4% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.